MacroGenics, Inc. - Common Stock (NQ:MGNX)

3.520 -0.060 (-1.68%)

Delayed Quote Updated: 10:43 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MacroGenics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

AutoNation, HubSpot, AMC Networks And Other Big Stocks Moving Higher On Friday ↗

February 17, 2023

U.S. stocks traded lower, with the Nasdaq Composite dropping over 100 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Around $11M Bet On Insight Enterprises? Check Out These 4 Stocks Insiders Are Buying ↗

February 17, 2023

Although US stocks closed lower on Thursday, there were a few notable insider trades.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 14, 2023

Via Benzinga

MacroGenics Posts Interim Data From Lorigerlimab Study In Prostate Cancer Patients ↗

February 14, 2023

Via Benzinga

MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium

February 13, 2023

From MacroGenics, Inc.

Via GlobeNewswire

The Latest Analyst Ratings for Macrogenics ↗

January 19, 2023

Via Benzinga

7 Analysts Have This to Say About Macrogenics ↗

November 23, 2022

Via Benzinga

MacroGenics to Participate in Upcoming Investor Conferences

February 06, 2023

From MacroGenics, Inc.

Via GlobeNewswire

Tesla To Rally Around 138%? Here Are 10 Other Analyst Forecasts For Thursday ↗

January 19, 2023

JP Morgan cut the price target for Apple Inc. (NASDAQ: AAPL) from $190 to $180. JP Morgan analyst Samik Chatterjee maintained an Overweight rating. Apple shares fell 1.1% to $133.70 in pre-market...

Via Benzinga

MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From MacroGenics, Inc.

Via GlobeNewswire

MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

January 04, 2023

From MacroGenics, Inc.

Via GlobeNewswire

Expert Ratings for Macrogenics ↗

November 23, 2022

Via Benzinga

What 7 Analyst Ratings Have To Say About Macrogenics ↗

November 23, 2022

Via Benzinga

$5 Million Bet On IAC? Check Out These 3 Stocks Insiders Are Buying ↗

November 28, 2022

Although US stocks closed mixed on Friday, there were a few notable insider trades.

Via Benzinga

Baidu To $180? Plus This Analyst Cuts PT On MacroGenics By 56% ↗

November 23, 2022

Mizuho cut the price target on Baidu, Inc. (NASDAQ: BIDU) from $200 to $180. Mizuho analyst James Lee maintained the stock with a Buy rating. Baidu shares rose 2.5% to trade at $97.49 on Wednesday.

Via Benzinga

Burlington Stores To Surge Over 21%? Plus Wedbush Slashes PT On Jack In The Box ↗

November 23, 2022

Barclays raised the price target on Burlington Stores, Inc. (NYSE: BURL) from $164 to $230. Barclays analyst Adrienne Yih maintained an Overweight rating on the stock. Burlington shares fell 0.1% to...

Via Benzinga

See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch ↗

November 23, 2022

Sales accelerated, again, in the third quarter. Here's what the company and analysts are watching.

Via Investor's Business Daily

Where Macrogenics Stands With Analysts ↗

November 23, 2022

Via Benzinga

Dow Jumps Over 300 Points; S&P 500 Rises 1% ↗

November 22, 2022

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Tuesday.

Via Benzinga

Why Shares of MacroGenics Were Dropping Tuesday ↗

November 22, 2022

Profit-taking and an analyst downgrade affected the stock's price.

Via The Motley Fool

Why Dollar Tree Shares Are Trading Lower By 10%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session ↗

November 22, 2022

Gainers Palisade Bio, Inc. (NASDAQ: PALI) shares jumped 99.1% to $4.42 after the company announced the FDA granted Fast Track designation to LB1148 for the acceleration of time to return of bowel...

Via Benzinga

Crude Oil Surges 2%; Best Buy Posts Upbeat Earnings ↗

November 22, 2022

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 250 points on Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 22, 2022

Via Benzinga

US Stocks Open Higher As Dow Surges 250 Points ↗

November 22, 2022

U.S. stocks traded higher this morning, with the Dow Jones gaining around 250 points on Tuesday.

Via Benzinga

First Drug That Can Delay Onset of Type 1 Diabetes Gets FDA Approval After Multiple Regulatory Hurdles ↗

November 18, 2022

Via Benzinga

Gap, Palo Alto Networks And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

November 18, 2022

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab

November 17, 2022

From MacroGenics, Inc.

Via GlobeNewswire

Why MacroGenics Stock Crushed the Market on Monday ↗

November 14, 2022

Positive momentum continues for the cancer specialist in the wake of its latest earnings report.

Via The Motley Fool

MacroGenics To Surge 138%? Plus This Analyst Sees $50 For Exact Sciences ↗

November 14, 2022

BMO Capital boosted the price target on MacroGenics, Inc. (NASDAQ: MGNX) from $5.7 to $16. BMO Capital analyst Etzer Darout upgraded the stock from Market Perform to Outperform. MacroGenics shares...

Via Benzinga

360 DigiTech, HUTCHMED And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

November 14, 2022

U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.